SB 200 family - Symic Bio

Drug Profile

SB 200 family - Symic Bio

Alternative Names: SB-200

Latest Information Update: 07 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator SYMIC Biomedical
  • Developer Symic Bio
  • Class Antineoplastics
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Research Breast cancer; Non-small cell lung cancer; Ovarian cancer; Pancreatic cancer

Most Recent Events

  • 11 Aug 2016 Early research in Breast cancer in USA (unspecified route)
  • 11 Aug 2016 Early research in Non-small cell lung cancer in USA (unspecified route)
  • 11 Aug 2016 Early research in Ovarian cancer in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top